Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. (Q55049410)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 June 2018

http://europepmc.org/abstract/MED/18358926

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 June 2018

http://europepmc.org/abstract/MED/18358926

0 references

1 reference

based on heuristic

inferred from title

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

object named as

Josef S Smolen

1 reference

Europe PubMed Central

PubMed publication ID

16 June 2018

author name string

Andre Beaulieu

2

1 reference

Europe PubMed Central

PubMed publication ID

16 June 2018

http://europepmc.org/abstract/MED/18358926

Andrea Rubbert-Roth

3

1 reference

Europe PubMed Central

PubMed publication ID

16 June 2018

http://europepmc.org/abstract/MED/18358926

Cesar Ramos-Remus

4

1 reference

Europe PubMed Central

PubMed publication ID

16 June 2018

http://europepmc.org/abstract/MED/18358926

Josef Rovensky

5

1 reference

Europe PubMed Central

PubMed publication ID

16 June 2018

http://europepmc.org/abstract/MED/18358926

Emma Alecock

6

1 reference

Europe PubMed Central

PubMed publication ID

16 June 2018

http://europepmc.org/abstract/MED/18358926

Thasia Woodworth

7

1 reference

Europe PubMed Central

PubMed publication ID

16 June 2018

http://europepmc.org/abstract/MED/18358926

Rieke Alten

8

1 reference

Europe PubMed Central

PubMed publication ID

16 June 2018

http://europepmc.org/abstract/MED/18358926

OPTION Investigators

9

1 reference

Europe PubMed Central

PubMed publication ID

16 June 2018

http://europepmc.org/abstract/MED/18358926

language of work or name

0 references

publication date

1 March 2008

1 reference

Europe PubMed Central

PubMed publication ID

16 June 2018

http://europepmc.org/abstract/MED/18358926

1 reference

Europe PubMed Central

PubMed publication ID

16 June 2018

http://europepmc.org/abstract/MED/18358926

371

1 reference

Europe PubMed Central

PubMed publication ID

16 June 2018

http://europepmc.org/abstract/MED/18358926

9617

1 reference

Europe PubMed Central

PubMed publication ID

16 June 2018

http://europepmc.org/abstract/MED/18358926

987-997

1 reference

Europe PubMed Central

PubMed publication ID

16 June 2018

http://europepmc.org/abstract/MED/18358926

New therapies for treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960453-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Evolving concepts of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960453-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960453-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960453-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960453-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960453-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Early rheumatoid arthritis: time to aim for remission?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960453-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessing remission in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960453-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytokine production by synovial T cells in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960453-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The paradigm of IL-6: from basic science to medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960453-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960453-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960453-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960453-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960453-5

7 January 2021

based on heuristic

inferred from DOI database lookup

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960453-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960453-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960453-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960453-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960453-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Fatigue in cancer patients compared with fatigue in the general United States population.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960453-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960453-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960453-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960453-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Innate inhibition of adaptive immunity: Mycobacterium tuberculosis-induced IL-6 inhibits macrophage responses to IFN-gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960453-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960453-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960453-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: A double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960453-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long‐term infliximab therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960453-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960453-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960453-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Joint swelling as a predictor of death from cardiovascular disease in a population study of Pima Indians

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960453-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiovascular risk factors, fitness and physical activity in rheumatic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960453-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960453-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(08)60453-5

1 reference

Europe PubMed Central

PubMed publication ID

16 June 2018

http://europepmc.org/abstract/MED/18358926

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 June 2018

http://europepmc.org/abstract/MED/18358926

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q55049410&oldid=1398097381"